Salud financiera de hoja de balance de Precigen

Salud financiera controles de criterios 4/6

Precigen tiene un patrimonio de los accionistas total de $118.5M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $151.0M y $32.5M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$62.86m
Patrimonio	US$118.50m
Total pasivo	US$32.55m
Activos totales	US$151.04m

Actualizaciones recientes sobre salud financiera

Recent updates

We're Keeping An Eye On Precigen's (NASDAQ:PGEN) Cash Burn Rate

Feb 28

Precigen: RRP Targeting With AdenoVerse Technology Platform

Jan 20

Will Precigen (NASDAQ:PGEN) Spend Its Cash Wisely?

Nov 04

Is Precigen (NASDAQ:PGEN) Using Debt In A Risky Way?

Jul 18

Things Look Grim For Precigen, Inc. (NASDAQ:PGEN) After Today's Downgrade

May 15

Some Shareholders Feeling Restless Over Precigen, Inc.'s (NASDAQ:PGEN) P/S Ratio

Apr 18

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

Nov 10

Precigen names Rutul Shah as chief operating officer

Sep 21

Circling Back On Precigen

Aug 23

Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

Aug 10

Precigen Q2 2022 Earnings Preview

Aug 07

Precigen to sell Trans Ova Genetics for $170M upfront

Jul 05

Precigen, Inc. (NASDAQ:PGEN) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 12

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

May 10

The Prognosis On Precigen

Jan 05

Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

Dec 31

Broker Revenue Forecasts For Precigen, Inc. (NASDAQ:PGEN) Are Surging Higher

Aug 12

Precigen (NASDAQ:PGEN) Is Carrying A Fair Bit Of Debt

Jul 16

Time To Worry? Analysts Are Downgrading Their Precigen, Inc. (NASDAQ:PGEN) Outlook

Mar 03

What Kind Of Investors Own Most Of Precigen, Inc. (NASDAQ:PGEN)?

Feb 12

Precigen announces positive preliminary data from early-stage PRGN-2009 cancer study

Jan 13

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($68.8M) de PGEN superan a sus pasivos a corto plazo ($23.0M).

Pasivo a largo plazo: Los activos a corto plazo de PGEN ($68.8M) superan a sus pasivos a largo plazo ($9.6M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: PGEN está libre de deudas.

Reducción de la deuda: PGEN no tiene deuda en comparación con hace 5 años, cuando su ratio deuda-patrimonio era de 56%.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: PGEN tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: PGEN tiene menos de un año de cash runway si el flujo de caja libre sigue creciendo a tasas históricas de 21.2% cada año.

Salud financiera de hoja de balance de Precigen

Salud financiera controles de criterios 4/6

Información clave

Actualizaciones recientes sobre salud financiera

We're Keeping An Eye On Precigen's (NASDAQ:PGEN) Cash Burn Rate

Will Precigen (NASDAQ:PGEN) Spend Its Cash Wisely?

Is Precigen (NASDAQ:PGEN) Using Debt In A Risky Way?

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

Recent updates

Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy

President exercised options and sold US$575k worth of stock

Full year 2023 earnings: EPS and revenues miss analyst expectations

Precigen, Inc. to Report Q4, 2023 Results on Mar 19, 2024

We're Keeping An Eye On Precigen's (NASDAQ:PGEN) Cash Burn Rate

Precigen: RRP Targeting With AdenoVerse Technology Platform

Precigen, Inc. Receives Orphan Drug Designation for PRGN- 2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission

Independent Director recently sold US$136k worth of stock

Forecast to breakeven in 2026

Consensus revenue estimates fall by 11%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Will Precigen (NASDAQ:PGEN) Spend Its Cash Wisely?

Independent Director recently bought US$688k worth of stock

Consensus revenue estimates decrease by 12%, EPS upgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Precigen, Inc Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval

President exercised options and sold US$58k worth of stock

Precigen, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Is Precigen (NASDAQ:PGEN) Using Debt In A Risky Way?

Precigen, Inc. Receives Breakthrough Therapy Designation for PRGN- 2012 Adenoverse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients

Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers

Precigen, Inc. Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastatic Cervical Cancer

Things Look Grim For Precigen, Inc. (NASDAQ:PGEN) After Today's Downgrade

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Precigen, Inc. to Report Q1, 2023 Results on May 10, 2023

Some Shareholders Feeling Restless Over Precigen, Inc.'s (NASDAQ:PGEN) P/S Ratio

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Precigen, Inc. has completed a Follow-on Equity Offering in the amount of $75 million.

Precigen, Inc. Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference

Precigen, Inc. Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients

Insufficient new directors

Price target increased to US$14.50

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

Precigen, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Precigen, Inc. Appoints Rutul R. Shah as Chief Operating Officer, Effective October 1, 2022

Precigen names Rutul Shah as chief operating officer

Chief Financial Officer recently bought US$51k worth of stock

Circling Back On Precigen

Independent Director recently sold US$115k worth of stock

Consensus revenue estimates fall by 66%

Independent Director notifies of intention to sell stock

Price target decreased to US$12.00

Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Precigen Q2 2022 Earnings Preview

Price target increased to US$13.75

Precigen, Inc. to Report Q2, 2022 Results on Aug 08, 2022

URUS Group LP agreed to acquire Trans Ova Genetics LC from Precigen, Inc. (NasdaqGS:PGEN) for $180 million.

Precigen to sell Trans Ova Genetics for $170M upfront

President exercised options and sold US$211k worth of stock

Consensus revenue estimates increase by 21%

Precigen, Inc. (NASDAQ:PGEN) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Precigen, Inc. Announces Impairment of Goodwill for Three Months Ended March 31, 2022

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

Precigen, Inc. Announces Impairment of Goodwill for Three Months Ended March 31, 2022

Precigen, Inc. to Report Q1, 2022 Results on May 09, 2022

Precigen, Inc., Annual General Meeting, Jun 09, 2022

Insufficient new directors

Precigen, Inc. Receives Fast Track Designation for PRGN-3006 UltraCAR-T® in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Consensus estimates of losses per share improve by 14%

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Precigen, Inc. to Report Q4, 2021 Results on Mar 01, 2022

The Prognosis On Precigen

Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

Precigen, Inc Announces Positive Interim Phase 1 Data for PRGN-3006 UltraCAR-T® in Relapsed or Refractory Acute Myeloid Leukemia

Insufficient new directors